TY  - JOUR
A1  - Ruiz, E. Josue
A1  - Diefenbacher, Markus E.
A1  - Nelson, Jessica K.
A1  - Sancho, Rocio
A1  - Pucci, Fabio
A1  - Chakraborty, Atanu
A1  - Moreno, Paula
A1  - Annibaldi, Alessandro
A1  - Liccardi, Gianmaria
A1  - Encheva, Vesela
A1  - Mitter, Richard
A1  - Rosenfeldt, Mathias
A1  - Snijders, Ambrosius P.
A1  - Meier, Pascal
A1  - Calzado, Marco A.
A1  - Behrens, Axel
T1  - LUBAC determines chemotherapy resistance in squamous cell lung cancer
JF  - Journal of Experimental Medicine
N2  - Lung squamous cell carcinoma (LSCC) and adenocarcinoma (LADC) are the most common lung cancer subtypes. Molecular targeted treatments have improved LADC patient survival but are largely ineffective in LSCC. The tumor suppressor FBW7 is commonly mutated or down-regulated in human LSCC, and oncogenic KRasG12D activation combined with Fbxw7 inactivation in mice (KF model) caused both LSCC and LADC. Lineage-tracing experiments showed that CC10(+), but not basal, cells are the cells of origin of LSCC in KF mice. KF LSCC tumors recapitulated human LSCC resistance to cisplatin-based chemotherapy, and we identified LUBAC-mediated NF-kappa B signaling as a determinant of chemotherapy resistance in human and mouse. Inhibition of NF-kappa B activation using TAK1 or LUBAC inhibitors resensitized LSCC tumors to cisplatin, suggesting a future avenue for LSCC patient treatment.
KW  - Solid tumors
Y1  - 2019
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-227146
VL  - 216
IS  - 2
ER  - 
TY  - JOUR
A1  - Peck, Barrie
A1  - Schug, Zachary T.
A1  - Zhang, Qifeng
A1  - Dankworth, Beatrice
A1  - Jones, Dylan T.
A1  - Smethurst, Elizabeth
A1  - Patel, Rachana
A1  - Mason, Susan
A1  - Jian, Ming
A1  - Saunders, Rebecca
A1  - Howell, Michael
A1  - Mitter, Richard
A1  - Spencer-Dene, Bradley
A1  - Stamp, Gordon
A1  - McGarry, Lynn
A1  - James, Daniel
A1  - Shanks, Emma
A1  - Aboagye, Eric O.
A1  - Critchlow, Susan E.
A1  - Leung, Hing Y.
A1  - Harris, Adrian L.
A1  - Wakelam, Michael J. O.
A1  - Gottlieb, Eyal
A1  - Schulze, Almut
T1  - Inhibition of fatty acid desaturation is detrimental to cancer cell survival in metabolically compromised environments
JF  - Cancer & Metabolism
N2  - Background
Enhanced macromolecule biosynthesis is integral to growth and proliferation of cancer cells. Lipid biosynthesis has been predicted to be an essential process in cancer cells. However, it is unclear which enzymes within this pathway offer the best selectivity for cancer cells and could be suitable therapeutic targets.

Results
Using functional genomics, we identified stearoyl-CoA desaturase (SCD), an enzyme that controls synthesis of unsaturated fatty acids, as essential in breast and prostate cancer cells. SCD inhibition altered cellular lipid composition and impeded cell viability in the absence of exogenous lipids. SCD inhibition also altered cardiolipin composition, leading to the release of cytochrome C and induction of apoptosis. Furthermore, SCD was required for the generation of poly-unsaturated lipids in cancer cells grown in spheroid cultures, which resemble those found in tumour tissue. We also found that SCD mRNA and protein expression is elevated in human breast cancers and predicts poor survival in high-grade tumours. Finally, silencing of SCD in prostate orthografts efficiently blocked tumour growth and significantly increased animal survival.

Conclusions
Our data implicate lipid desaturation as an essential process for cancer cell survival and suggest that targeting SCD could efficiently limit tumour expansion, especially under the metabolically compromised conditions of the tumour microenvironment.
KW  - SCD
KW  - lipidomics
KW  - prostate cancer
KW  - breast cancer
KW  - lipid desaturation
Y1  - 2016
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-145905
VL  - 4
IS  - 6
ER  -